Loading…
Vicore Pharma Holding AB
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in VCRE.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| SMTISanara MedTech Inc. | $34.57 | — | 45.1x | — | -1.32% | $317.63M |
| RCELAVITA Medical, Inc. | $10.35 | — | — | — | — | $320.09M |
| ABEOAbeona Therapeutics Inc | $5.53 | — | 2.5x | — | -43.13% | $316.23M |
| EMBCEmbecta Corp. | $5.58 |
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis. It has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.
Company description provided by Yahoo Finance.
| 3.8x |
| — |
| 5.73% |
| — |
| $316.16M |
| EYPTEyePoint, Inc. | $3.72 | — | 9.4x | — | -148.70% | $320.71M |
| PRQRProQR Therapeutics N.V. | $2.29 | — | 2.7x | — | -57.40% | $323.16M |